Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

Sumbul, Ahmet; Disel, Umut; Sezgin, NURZEN; Sezer, Ahmet; Kose, Fatih; Besen, Ali; Sumbul, Zehra; Abali, Huseyin; Ozyilkan, Ozgur

doi:10.12659/msm.889945

Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

Copy For Citation

Sumbul A. T. , Disel U., Sezgin N. , Sezer A., Kose F., Besen A. A. , ...More

MEDICAL SCIENCE MONITOR, vol.20, pp.428-433, 2014 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 20
Publication Date: 2014
Doi Number: 10.12659/msm.889945
Title of Journal : MEDICAL SCIENCE MONITOR
Page Numbers: pp.428-433

Abstract

Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy.